By Fineline Cube 
Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues of RMB 935.22 million (approximately USD 136.92 million), representing a 25.84% year-over-year increase.
Financial Performance Summary
| Metric | 2025 Result | YoY Change | Primary Drivers |
|---|---|---|---|
| Total Revenue | RMB 935.22M (USD 136.92M) | +25.84% | Qletli & Shiruili sales growth; Starjemza US launch |
| Revenue Streams | Sales + License Income | Expanded | Dual revenue model strengthening |
| Market Coverage | 3,500+ hospitals; 2,500+ pharmacies | Continued expansion | Nationwide commercial network |
Product Portfolio Highlights
- Qletli (adalimumab biosimilar): Established product showing steady sales growth in Chinese market
- Shiruili (tocilizumab biosimilar): Contributing significantly to domestic revenue stream
- Starjemza (ustekinumab biosimilar): Recently launched in US market, creating new international revenue channel and licensing opportunities
Commercial Infrastructure Development
During 2025, Bio-Thera implemented systematic enhancements to its marketing organization through refined management practices:
- Team Structure: Optimized division of responsibilities among nationwide regional teams
- Coordination: Enhanced cross-regional coordination mechanisms
- Strategy Execution: Ensured precise implementation of sales strategies
- Resource Allocation: Improved efficiency in market resource deployment
Market Penetration Metrics
| Coverage Area | Status | Details |
|---|---|---|
| Geographic Reach | Nationwide | All provinces, municipalities, and autonomous regions except Tibet, Hong Kong, Macao, and Taiwan |
| Hospital Access | 3,500+ | Prescribing hospitals across mainland China |
| Pharmacy Distribution | 2,500+ | Specialty and social pharmacies nationwide |
| Growth Trajectory | Expanding | Increasing both breadth and depth of market coverage |
Strategic Outlook
Bio-Thera’s dual-pronged strategy of strengthening its domestic commercial infrastructure while expanding internationally through biosimilar launches positions the company for continued growth. The successful US market entry with Starjemza establishes a precedent for future international expansion of its biosimilar portfolio, potentially creating additional licensing revenue streams beyond direct product sales.
Forward-Looking Statements
This brief contains forward-looking statements regarding Bio-Thera Solutions’ financial performance, market expansion, and commercial strategy. Actual results may differ due to risks including market competition, regulatory changes, and execution challenges.-Fineline Info & Tech